Latest GLP-1 Research: What Changed in 2026 (And What It Means for You)

The latest GLP-1 research has produced two newly available U.S. options in 2026: Wegovy HD, approved March 19, and Foundayo, approved April 1. Wegovy tablets arrived just before them on December 22, 2025. Retatrutide, CagriSema, and survodutide are still investigational and unavailable as approved prescriptions. Retatrutide produced one of the largest phase 3 weight-loss results reported so far, but no FDA application or verified launch date has been announced.

Home › GLP-1 Research › Latest GLP-1 Research

Published by Weight Loss Provider Guide
Last verified: August 5, 2026 · Evidence Ledger v1.1 · Next scheduled review: September 1, 2026
View change log ↓ · Download the ledger (CSV)

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. This page contains no paid placements. We have commercial relationships elsewhere on this site, including one clearly disclosed affiliate link to Ro's free insurance-coverage tool below. We may earn a commission if a reader later enrolls through that link. Those relationships did not decide which studies appear here or how we grade them. The matching quiz is our own tool. This page is medical information, not an individualized diagnosis, prescription, or treatment plan.

Here's the short version of the latest GLP-1 research: the two 2026 changes you can act on already happened, and both are sitting in pharmacies right now. Wegovy HD — a 7.2 mg semaglutide shot for certain adults who have already tolerated 2.4 mg — was approved March 19, 2026. Foundayo (orforglipron), the first FDA-approved nonpeptide small-molecule GLP-1 tablet for chronic weight management, was approved April 1, 2026. Its regular cash price is dose-tiered from $149 to $349 per 30-day supply, rather than a flat $149 at every dose.

Everything else behind the biggest pipeline headlines is still experimental. That includes retatrutide, the drug behind the “28% weight loss” coverage. Lilly has not announced an FDA filing or a commercial launch date.

So if you've been holding off because something stronger is guaranteed to arrive soon, the headline does not give you that certainty. The approved choices changed. The experimental timeline did not become a promise.

Now for the part almost nobody tells you. We pulled the major weight-loss numbers published between late 2025 and today and put them side by side. The same trial can produce two different headline numbers because it answers two different statistical questions. And among the aligned treatment-policy or treatment-regimen estimates we could compare, the placebo groups lost from 0.6% to 5.4% — a nine-fold spread that makes casual cross-trial rankings look more precise than they are.

We'll show you all of it below, with the sources, so you can check us.

Fair warning up front: this page won't tell you which drug is right for you. Nothing on the internet can do that. What it will do is show you how strong each finding really is, who was actually studied, whether the FDA has signed off, and — the part we care most about — what each result does not prove.

The 60-second version

Jump to the full evidence ledger →

Use the interactive filters when this page is built: Approved now · Randomized human evidence · Negative results · Safety signals · Investigational pipeline. The complete, crawlable ledger remains visible in HTML even when JavaScript is off.

What is the latest GLP-1 research showing right now?

The strongest evidence today supports meaningful weight reduction, plus cardiovascular and kidney benefits in specific groups of people. Newer areas — Alzheimer's disease, addiction, cancer prevention, precision genetics, and several next-generation drugs — are mixed, early, negative, or still awaiting FDA review. The study design, estimand, outcome, and group studied matter as much as the headline number.

Five things are true right now, and they're the frame for everything below.

1. Weight loss works, but how much depends on more than the drug. Dose, treatment duration, diabetes status, tolerability, adherence, statistical estimand, and the trial's missing-data rules can move the reported number by several percentage points.

2. Heart and kidney benefits are real — for specific people. Not “GLP-1s protect your organs.” Specific drug, specific population, specific outcome.

3. Some uses beyond weight are now FDA-approved. Others are not. Semaglutide has an accelerated-approval indication for a defined noncirrhotic MASH population. Tirzepatide has an obstructive-sleep-apnea indication in adults with obesity. Alcohol use disorder, Alzheimer’s disease, cancer prevention, and HFpEF are not current U.S. indications for these drugs merely because trials examined them.

4. Several new drugs have strong trial results and zero approved availability. A great phase 3 is not a prescription.

5. Failures matter as much as wins. The Alzheimer’s program failed to improve the clinical outcome. CagriSema missed noninferiority to tirzepatide in a later head-to-head. If a page only shows you the exciting stuff, it isn't telling you the truth.

One quick thing about words

People say “GLP-1” for everything. It's easier. But the drugs on this page don't all work the same way.

• Semaglutide (Wegovy, Ozempic) — a GLP-1 receptor agonist.
• Tirzepatide (Zepbound, Mounjaro) — a GIP/GLP-1 dual agonist.
• Retatrutide — an investigational GIP/GLP-1/glucagon triple agonist.
• Survodutide — an investigational glucagon/GLP-1 dual agonist.
• CagriSema — an investigational fixed-dose combination of cagrilintide, an amylin analogue, plus semaglutide.
• Orforglipron (Foundayo) — a nonpeptide small-molecule GLP-1 receptor agonist taken as a tablet with or without food.

Target count alone does not rank efficacy or tolerability. Direct comparative trials do. A triple agonist can produce a large result; that does not mean “three targets” automatically beats “two targets” in every population or that the trade-off will be acceptable for every person.

How we label evidence

Every finding here gets a grade. Here's what they mean, in plain terms.

We keep four things separate, on purpose:

• Was it published? Peer-reviewed paper, regulatory document, or company announcement?
• How was the number estimated? Treatment-policy/treatment-regimen or trial-product/efficacy estimand?
• Is it approved? Approved for this use, approved for something else, under review, or not approved at all?
• Does it apply to you? Who was actually in the trial?

Here's the sentence that trips most people up: a great trial is not FDA approval, and FDA approval doesn't mean a drug is right for you. Those are separate gates. Most headlines blur them.

The GLP-1 evidence ledger: every major finding since late 2025

This v1.1 ledger contains 18 material findings and regulatory boundaries verified through August 5, 2026. It places the result, publication status, FDA status, availability, and “what it does not prove” in the same row. That last column is the one we built this page for.

Every other roundup tells you what a study found. Almost none tell you where the finding stops.

Our original contribution is the assembly, not the underlying studies. The evidence grade, regulatory-status crosswalk, aligned estimand table, active-minus-placebo arithmetic, “what this changes,” and “what this does not prove” fields are Weight Loss Provider Guide's reproducible framework. The trial findings belong to the investigators, sponsors, journals, and regulators cited below.

Here's the honest part. The most impressive average on this page belongs to a drug you cannot get as an FDA-approved prescription. Retatrutide's 28.3% result is real within the sponsor's stated efficacy estimand. Its 25.0% treatment-regimen estimate is real too. There is no announced FDA filing or verified pharmacy date.

If you came here hoping the news means a specific experimental drug is about to change your options, it may not. What changed in 2026 is already on the shelf. What happens next is still a trial-and-regulatory question.

We'd rather say that now than let a press-release number make the decision for you.

Why aren't the weight-loss numbers you're comparing actually comparable?

Recent obesity trials often report more than one estimand: an idealized trial-product or efficacy estimate and a treatment-policy or treatment-regimen estimate that incorporates discontinuation and other post-randomization events under the trial's statistical rules. Mixing those estimates across drugs can create a several-point illusion before the drugs themselves are even compared.

This is the single most useful thing on this page. Stay with us for four minutes.

The two questions hiding behind one headline

A modern obesity trial may answer two different questions.

Question 1 — “What was the estimated effect under the trial-product or efficacy scenario?” This generally estimates what would happen if participants stayed on the assigned study intervention, with the exact assumptions defined in the protocol. It is not simply a raw average of “completers,” but it is closer to an idealized on-treatment question.

Question 2 — “What was the estimated effect regardless of discontinuation or specified rescue treatment?” Sponsors call this a treatment-policy or treatment-regimen estimand. It includes everyone randomized under a model that accounts for what happened after treatment changes. It is not identical to ordinary clinical practice, but it usually produces a more conservative number.

The gap can be several percentage points. On a drug with more discontinuation or more post-randomization treatment changes, it can be wider.

Neither number is automatically dishonest. But if one article quotes the efficacy estimand for Drug A and the treatment-policy estimand for Drug B, you are not comparing the drugs. You are comparing the questions.

What we found when we aligned the question

We rebuilt the table using each trial's treatment-policy or treatment-regimen estimate where the primary source reported one. Then we subtracted the aligned placebo estimate. The subtraction is our arithmetic.

Method note: “Active-minus-placebo” is a descriptive subtraction, not a causal head-to-head estimate and not a drug ranking. Differences across trials can reflect population, duration, lifestyle support, dose escalation, estimand, missing-data rules, rescue treatment, adherence, and chance.

Look at the placebo column.

The placebo groups lost between 0.6% and 5.4% of body weight. That's a nine-fold spread across trials that all included some form of lifestyle intervention but did not run the same protocol in the same people for the same length.

Why does that matter? Because the placebo arm shows what happened under that trial's background program and statistical rules without the investigational drug. When one placebo group loses 5.4% and another loses 0.6%, subtracting placebo can help expose the difference — but it cannot erase all the other design differences.

The clearest example is survodutide. Its aligned high-dose estimate was 13.0%, while placebo lost 5.4%, producing a 7.6-point descriptive difference. That does not prove the drug's “true effect” is 7.6 points, and it does not prove another drug is better. It proves the 13.0% headline is inseparable from a trial in which placebo participants lost an unusually large amount.

We have not seen another consumer page place the aligned estimand, placebo result, duration, regulatory status, and non-comparability warning in one table. The arithmetic is simple. The source alignment is the work.

The 26-week trap

Look at the last row.

Elecoglipron's 10.5% came from a 26-week trial. Retatrutide's 25.0% treatment-regimen estimate came from an 80-week trial.

Weight trajectories on these drugs can continue for many months before flattening. Comparing a 26-week number to an 80-week number is like comparing a half marathon time to a full marathon time and declaring a winner.

Rule of thumb: if two numbers come from trials of different lengths, different populations, or different estimands, you do not have a direct comparison. You have separate findings.

The retatrutide number problem we resolved

The draft version of this page treated two sets of TRIUMPH-1 figures as a conflict. They are not.

Lilly's May 21 release reported both sets and identified the estimands:

• Efficacy estimand: 19.0%, 25.9%, and 28.3% at the three doses, versus 2.2% with placebo.
• Treatment-regimen estimand: 17.6%, 23.7%, and 25.0%, versus 3.9% with placebo.

The widely repeated 30.3% figure is a third, later result. It came from a prespecified blinded extension involving 532 participants who entered with a BMI of at least 35, completed 80 weeks, tolerated their assigned dose, and continued to week 104. That makes it a real result in a narrower, treatment-tolerant extension group — not the average result for everyone randomized in the original 80-week population.

We use 28.3% when discussing the sponsor's efficacy estimand, 25.0% in the aligned treatment-regimen table, and 30.3% only when describing the prespecified 104-week extension.

We still treat all three as preliminary until the complete peer-reviewed paper is available.

The cleanest direct comparison between approved injectables

Everything above compares across separate trials, which is always limited.

SURMOUNT-5 randomized 751 adults with obesity, without type 2 diabetes, to tirzepatide or semaglutide in the same 72-week, open-label trial using maximum tolerated doses.

Result: 20.2% with tirzepatide and 13.7% with semaglutide.

That is the strongest direct evidence that tirzepatide produced greater mean weight loss than semaglutide in the population and dosing conditions studied. It does not prove the same gap at every dose or for every patient.

CagriSema's REDEFINE 4 also provides a direct comparison, but it answers a different question: the investigational combination missed the prespecified noninferiority test against tirzepatide. That is why “only one head-to-head exists” is no longer accurate.

Should you wait for the next GLP-1 drug, or start with an approved option now?

Do not postpone an otherwise appropriate, clinician-recommended approved treatment solely because an investigational drug has a bigger press-release number. Waiting can make sense when your clinician recommends it, a known coverage change is close, or a suitable clinical trial is available — but no unapproved pipeline drug on this page has a guaranteed U.S. launch date.

This is the question underneath the search. Let's answer it directly.

The availability clock

How we built this. The table states current regulatory and development milestones only. It does not convert a typical review clock into a launch prediction. Trials can fail, filings can be delayed, review timelines can change, and an approved drug can launch with access constraints.

Three situations where waiting genuinely can make sense

1. Your clinician thinks the current approved options are not appropriate right now. That can be about contraindications, prior adverse effects, other medical conditions, pregnancy planning, medication interactions, or a reason specific to your history. A bigger trial average does not override individual safety.

2. You qualify for a clinical trial that answers the question you care about. Trial participation may provide study-related care and access to an investigational intervention, but eligibility is strict and some trials use placebo or active comparators. Search ClinicalTrials.gov by drug, condition, recruiting status, and location.

3. Your coverage changes on a known date. If your employer plan adds weight-management coverage on January 1, waiting a short, defined period can be arithmetic rather than procrastination. Verify the formulary, prior-authorization criteria, effective date, deductible, and any exclusions in writing.

What waiting actually costs — and what it does not tell us

If you wait for retatrutide, you are not choosing between “28% now” and “20% now.” You are choosing between an approved option that may be available now and an experimental option that may or may not be approved later.

The cost of waiting can include more time with untreated obesity-related risk, more time navigating symptoms or limitations, and the possibility that the future drug is delayed or not a fit. The cost of starting can include adverse effects, medication expense, prior-authorization work, and the possibility that your first choice is not effective or sustainable.

That is why the right question is not “Which headline is largest?” It is:

What approved option is medically appropriate, affordable enough to continue, and acceptable enough that I will actually use it — and what would make us change course?

Not sure whether you're dealing with a medical-fit question, a coverage question, or a wait-for-a-trial question? That's a fair place to be. The answer depends on what you have tried, what your plan covers, which formulations you will use, and where you live.

Take the free 60-second GLP-1 path quiz → and get a personalized action map of the legitimate routes that may exist for your situation. No account needed. The quiz does not diagnose you, determine medical eligibility, or prescribe treatment.

Which new GLP-1 drugs actually matter in 2026?

Three newer formulations or products are approved and available: Foundayo, Wegovy HD, and Wegovy tablets. Three high-profile programs — retatrutide, CagriSema, and survodutide — have pivotal evidence but no approved U.S. product. A later wave includes oral drugs, monthly-maintenance programs, and an incretin being studied specifically in adults with type 1 diabetes and overweight or obesity.

Available now

Foundayo (orforglipron) — the nonpeptide small-molecule pill. Approved April 1, 2026 as the first new molecular entity cleared under the FDA's Commissioner’s National Priority Voucher program and the first FDA-approved nonpeptide small-molecule GLP-1 tablet for chronic weight management. It can be taken once daily with or without food and without a specified water-volume or waiting-period rule.

That distinction matters because Wegovy tablets came first as an oral weight-management GLP-1 product, in December 2025, but they are peptide semaglutide and carry specific empty-stomach instructions.

Foundayo carries a boxed warning about the potential risk of thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. The current label also lists warnings and precautions including pancreatitis, severe gastrointestinal reactions, acute kidney injury due to volume depletion, hypoglycemia in relevant settings, hypersensitivity, diabetic retinopathy complications in people with type 2 diabetes, acute gallbladder disease, and pulmonary aspiration during anesthesia or deep sedation.

The regular 30-day self-pay price is dose-tiered: $149 at 0.8 mg, $199 at 2.5 mg, $299 at 5.5 or 9 mg, and $349 at 14.5 or 17.2 mg. Eligible self-pay users who refill a high dose within the program's stated window may pay $299; commercial-insurance savings can be as low as $25 for eligible patients. Terms can change.

Wegovy HD 7.2 mg — the higher-dose semaglutide injection. Approved March 19, 2026. This is a step-up, not a starting point: the label says adults who tolerate 2.4 mg for at least four weeks may increase to 7.2 mg when additional weight reduction is clinically indicated.

In the FDA label's Study 8, the estimated mean change at week 72 was 18.8% with 7.2 mg, 15.5% with 2.4 mg, and 3.9% with placebo. The sponsor's trial-product analysis produced the widely quoted 20.7% number. About a third reached at least 25% loss in that idealized analysis.

Wegovy tablets 25 mg — approved December 22, 2025. It is once-daily oral semaglutide for weight reduction and cardiovascular risk reduction in labeled adults. The dosing ladder is 1.5 mg, 4 mg, 9 mg, then 25 mg maintenance.

The convenience trade-off is not “pill means no rules.” The tablet must be taken on an empty stomach after an overnight fast with no more than 4 ounces of plain water, followed by at least 30 minutes before food, beverages, or other oral medication.

Strong results, not approved

Retatrutide — three receptor targets in one weekly investigational injection. TRIUMPH-1 produced one of the largest mean reductions reported in a phase 3 obesity-drug program. It also showed a dose-related tolerability trade-off: adverse-event discontinuation was 4.1% at 4 mg, 6.9% at 9 mg, and 11.3% at 12 mg, versus 4.9% with placebo. Dysesthesia occurred more often at higher doses. No FDA application or commercial date has been announced.

CagriSema — semaglutide plus cagrilintide, an amylin analogue. Novo Nordisk filed the NDA on December 18, 2025, using the REDEFINE 1 and 2 programs. The NDA was submitted before the later REDEFINE 4 head-to-head result. In February 2026, CagriSema missed its prespecified noninferiority test against tirzepatide: the sponsor reported 23.0% versus 25.5% under the trial-product estimand and 20.2% versus 23.6% under the treatment-policy estimand. Novo says it expects a U.S. decision in Q4 2026; the FDA has not posted a public target date.

That later result matters. It does not automatically determine the FDA decision, and it does not erase the placebo-controlled efficacy. It does kill the simple story that adding amylin necessarily produces a superior weight-loss product.

Survodutide — a glucagon/GLP-1 dual agonist. The weight result is less striking than retatrutide's, but the body-composition and liver data are worth watching. In an MRI substudy with about 25 people per group, the 6 mg dose reduced total fat volume by 27.8%, visceral fat by 34.0%, and liver fat by 63.1%, while lean volume fell 9.8% versus 2.9% with placebo. That sample is small. Treat it as a signal, not a settled body-composition advantage.

In a separate 216-person MASLD trial, 68.5% under the treatment-regimen analysis achieved at least a 30% reduction in liver fat versus 28.6% with placebo. Under the efficacy analysis, the corresponding figures were 84.2% and 24.3%.

The next wave

Berobenatide is the one we'd watch for behavior, not because it has the biggest number. Going from 52 injections a year to 12 could change who is willing to continue treatment. That is an editorial judgment about convenience, not a claim that the product will be approved or more effective.

Acmopatide matters for a different reason. In a 16-week phase 2 study of 111 adults with type 1 diabetes and overweight or obesity, the 4.1 mg group had a 0.34-percentage-point A1C reduction from baseline; weight loss reached about 6.7% at the highest reported dose, and daily insulin requirements fell by as much as 15%. It remains preliminary and does not establish long-term hypoglycemia, ketoacidosis, cardiovascular, or durability outcomes.

Are the new GLP-1 pills as good as the shots?

There's no universal answer because formulation is not the only thing changing between trials. The approved pills produced substantial mean weight loss, but the strongest approved injectable averages are larger in separate studies. No direct randomized obesity trial has compared a specific approved GLP-1 pill with a specific approved injection under the same rules.

Here's what we can say honestly.

On separate trial averages, the strongest injections still lead. SURMOUNT-5 reported 20.2% with tirzepatide, and the Wegovy HD label reports 18.8% under its intention-to-treat approach. Foundayo's pivotal no-diabetes trial reported 11.1% at the 17.2 mg dose versus 2.1% with placebo. Wegovy tablets reported 13.6% versus 2.4% in the current label.

But we cannot call that a fair fight. Different populations, lengths, titration schedules, estimands, rescue rules, discontinuation patterns, and background programs.

The primary sources also resolve a confusion in the draft. The different orforglipron numbers circulating online came from different doses, populations, analyses, or development-stage formulations. For the FDA-approved 17.2 mg dose in adults without diabetes, the current U.S. label reports an estimated 11.1% versus 2.1% at week 72. That is the number to anchor to unless a later head-to-head answers a different question.

What a real comparison would need: same trial, randomization, same population, same duration, clinically appropriate approved doses, same estimand, same lifestyle program, and the same handling of missing data and discontinuation. That trial has not been run for an approved weight-management pill versus an approved injection.

Who the pill actually fits

Averages aren't the whole story here. Adherence is.

The pill may make sense if:

• Needles are the main reason you have not pursued treatment.
• Daily dosing is easier for your routine than a weekly injection.
• You travel frequently and injection storage or transport is a real barrier.
• You and your prescriber prefer the specific label, contraindication profile, and evidence for an oral option.
• Foundayo's lack of fasting and water-timing rules solves a practical problem for you.

The shot may make more sense if:

• A weekly schedule is easier to remember than a daily schedule.
• You are already doing well on an injection and there is no clear clinical reason to switch.
• You and your clinician prioritize the strongest direct and phase 3 evidence currently available for approved injectables.
• The tablet's administration instructions or daily routine would make adherence worse.

Do not assume a prior reaction to an injectable disappears with a pill. Class-related effects can still occur, and switching products may require a new titration with symptoms that recur.

There's a real trade-off nobody names: a weekly injection is one scheduled dose per week. A daily pill is seven. For some people that's easier. For others it's six more chances to forget.

How do you get an FDA-approved GLP-1 now, and what does it cost?

The three practical paths are insurance, a manufacturer-supported self-pay channel, or a clinical telehealth program. Insurance can produce the lowest out-of-pocket cost when coverage is strong, but deductibles and coinsurance can make self-pay competitive. The exact price depends on drug, dose, eligibility, plan design, and whether a separate care membership is charged.

The three doors

Insurance. When the plan covers the drug, this can be the lowest-cost path. It may require prior authorization, step therapy, documented eligibility, or a specific prescriber. “Covered” does not automatically mean cheap; check deductible, coinsurance, copay, quantity limits, and renewal rules.

Manufacturer-supported self-pay. Lilly and Novo Nordisk publish direct or supported cash prices for eligible prescriptions. These are medication prices, not medical-care memberships. Terms, dose tiers, refill windows, and eligibility rules matter.

Telehealth. A telehealth program can bundle the clinical evaluation, prescription management, follow-up, and insurance paperwork. The trade-off is that a membership or visit charge may sit on top of the medication cost.

What the approved products cost right now

Verified August 5, 2026. Manufacturer programs can change or end. Taxes, pharmacy fees, insurance copays, and clinical-program fees can differ.

Eligible commercially insured patients may pay less through savings programs. Eligible Medicare beneficiaries may have separate 2026 bridge pricing for covered GLP-1 weight-management products. Eligibility and product coverage are not universal.

Provider-stated versus independently verified: Ro

We are going to point you at one paid partner on this page, so here's the full picture first.

The honest catch

Ro's membership is separate from the medication. If you already have a clinician who will prescribe and manage an appropriate FDA-approved product, and you do not need coverage support or ongoing telehealth care, paying a membership can cost more than using a manufacturer-supported pharmacy route directly.

But that separate program can be useful when the problem is not merely “where do I buy the drug?” Ro includes clinician access, follow-up, dose and side-effect management, and insurance support. Its coverage checker is available without joining and gives a report you can share with your existing clinician.

That last part is why we're mentioning it here at all.

Before you decide whether to wait, find out what your plan actually covers. A coverage report turns a vague fear about cost into a concrete answer you can bring to your clinician.

→ Check Ozempic pen, Wegovy pen, and Zepbound pen coverage with Ro's free GLP-1 Insurance Coverage Checker

Ro says the checker is free and does not prescribe or submit a treatment request. It cannot currently check Foundayo, Wegovy tablets, or Zepbound KwikPen. Ro Body membership starts at $39 for the first month, then ranges from $74 to $149 per month depending on prepayment; medication costs extra. This is an affiliate link. We may earn a commission if you later enroll, at no added cost to you. Replace this public URL with the correct tracked affiliate URL in the CMS before publishing.

For a broader breakdown without a provider recommendation, use our current GLP-1 cost guide.

What does GLP-1 research show beyond weight loss?

The strongest evidence outside weight is in cardiovascular outcomes, kidney outcomes, selected liver disease, obesity-related HFpEF, and obstructive sleep apnea. Each result belongs to the exact drug, population, endpoint, and regulatory status studied. None proves that every GLP-1-based drug protects every organ in every person.

This is where headlines do the most damage, because they drop the population or quietly turn a trial result into an FDA indication.

Two things worth pausing on

The SELECT numbers deserve a closer look. The event rates were 6.5% and 8.0% — an absolute difference of 1.5 percentage points over the study period. Reported relatively, that becomes a 20% reduction. Both describe the same trial. The raw rates tell you how often the outcome occurred; the relative reduction tells you the proportional change.

When you see a large percentage in a headline, look for the two raw numbers underneath it. They're usually the more useful pair.

SUMMIT is a strong result without a matching U.S. indication. Tirzepatide reduced the trial's composite outcome in obesity-related HFpEF. The current Zepbound label lists chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity — not HFpEF. Trial evidence and approval status are two separate facts, and both belong in the answer.

Where the line is

No GLP-1-based drug has an established U.S. indication for cancer prevention or longevity. Earlier observational dementia associations also did not survive the major randomized Alzheimer’s test.

Observational studies are useful for generating questions. They're weaker for answering causal ones because treated and untreated groups can differ in disease severity, healthcare access, prescribing patterns, weight change, adherence, and many factors the study did not fully measure.

We know this isn't theoretical, because the Alzheimer's story just showed us.

What GLP-1 research failed — or forced a harder trade-off — in 2026?

Two major programs delivered a clear disappointment: oral semaglutide did not slow Alzheimer's disease, and CagriSema missed noninferiority to tirzepatide. A third study did not “fail,” but it exposed a real trade-off: preserving more lean mass during tirzepatide treatment did not create dramatically greater scale-weight loss.

Most pages don't have this section. That's exactly why we do.

Alzheimer's: EVOKE and EVOKE+. For years, observational and preclinical work created hope that GLP-1 treatment might reduce dementia risk or slow disease. Novo Nordisk ran two large randomized trials — 3,808 people across 40 countries, all with confirmed early symptomatic Alzheimer's disease.

Oral semaglutide did not slow clinical progression. Some biological markers moved, but the outcome that mattered to patients did not. The extension studies were stopped. The result was published in 2026.

That's the cleanest lesson available about observational data. The hopeful signal was worth testing. The signal did not survive the randomized clinical test.

CagriSema versus tirzepatide. In REDEFINE 4, CagriSema missed the prespecified noninferiority test. Novo reported 23.0% versus 25.5% under the trial-product estimand and 20.2% versus 23.6% under the treatment-policy estimand.

CagriSema can still have a favorable benefit-risk profile and can still be approved. What the result blocks is the easy assumption that a GLP-1/amylin combination must match or beat tirzepatide.

The muscle-preservation trade-off: EMBRAZE. The draft described apitegromab as a muscle drug that “backfired.” That was too strong. In the 102-person phase 2 trial, adding apitegromab to tirzepatide preserved about 1.9 kg more lean mass at 24 weeks while total weight loss was broadly similar.

That is not a failure. It is a clue that scale weight and body composition can pull in different directions. A treatment that preserves more lean tissue may not produce a larger scale change, yet could still matter for strength, function, and long-term health. Larger and longer trials must show whether the preserved tissue produces meaningful functional benefit.

What does the latest GLP-1 safety research say?

Gastrointestinal effects remain the most common tolerability problem across these drugs, but the exact rates and warnings are product-specific. In January 2026, FDA found no increased risk of suicidal thoughts or behavior and requested warning removal. Newer issues — dysesthesia, an observational eye signal, and lean-mass change — need accurate numbers without turning a signal into either panic or dismissal.

Start with the label, not with a generic list

There's no single “GLP-1 side effect list.” Each drug and formulation has its own current prescribing information. Foundayo's label, for example, lists hair loss among common adverse reactions and has product-specific wording in its boxed warning. Wegovy HD adds high-dose safety data not present in older 2.4 mg summaries.

Read the current label for the specific drug and dose you are considering. We link the primary labels in the sources.

Who is discontinuing, and at what dose?

One number that matters alongside efficacy is the share who permanently stop because of adverse events.

Read the survodutide row again. About one in five people assigned to the high dose permanently discontinued because of adverse events. A result among a trial population has to be read beside the number who could not or did not stay on it.

This is why we put discontinuation next to efficacy. They are two halves of the same decision.

The sensation signal at higher doses

Both Wegovy HD and retatrutide reported dysesthesia — altered skin sensations that can include tingling, burning, pain, or unusual sensitivity.

In the Wegovy HD label, dysesthesia was reported in 22% at 7.2 mg, 6% at 2.4 mg, and 0.3% with placebo. Most events were described as mild or moderate. Among patients reporting dysesthesia, 2% on 7.2 mg permanently discontinued Wegovy because of it.

In TRIUMPH-1, Lilly reported dysesthesia in 5.1%, 12.3%, and 12.5% across the three retatrutide doses, versus 0.9% with placebo.

That is real information for anyone weighing a high-dose step-up. It is not proof that every tingling sensation is caused by the drug, and it does not replace evaluation of new neurologic or skin symptoms.

Muscle loss: the number people keep turning into the wrong conclusion

You lose some lean tissue during substantial weight loss by many methods — dieting, surgery, and medication. “Lean mass” is not identical to skeletal muscle, and a body-composition scan does not tell you by itself whether strength or function changed.

A 2026 European consensus offered a practical reference: roughly a 3:1 ratio of fat loss to lean-mass loss can be used as an illustrative guide when body composition is available. The authors did not present it as a validated pass/fail target for every patient.

The useful parts of the guidance are the behaviors and measurements:

• Use progressive resistance exercise as the clearest practical lever for preserving strength and function, while recognizing that the evidence does not establish one universal program.
• Support adequate nutrition and protein intake based on individual needs, kidney function, age, and clinician or dietitian advice.
• Do not rely on BMI alone. Weight, waist circumference or waist-to-height ratio, and functional measures answer different questions.
• Track function. Grip strength, sit-to-stand performance, walking ability, and day-to-day function can matter more than one scan compartment.
• Screen for risks that affect nutrition and safety, including disordered eating and problematic alcohol use when clinically relevant.

The 3:1 reference is useful because it creates a conversation. It is not a warranty.

Older adults, people with frailty, and anyone already at risk of sarcopenia deserve this conversation before substantial weight loss, not after.

The eye signal

A large observational target-trial emulation in U.S. veterans with type 2 diabetes reported a higher relative risk of NAION — a sudden optic-nerve injury — after semaglutide initiation than after initiation of an SGLT2 inhibitor.

Three things can be true at once: the absolute event frequency was low, the design cannot prove causation, and the mostly older male veteran population limits how far the result generalizes.

Practical takeaway: sudden vision loss or a sudden major visual-field change needs urgent, same-day evaluation. That is true regardless of whether a GLP-1 drug caused it.

The warning FDA asked to remove

In January 2026, FDA finished its review of suicidal thoughts and behavior with GLP-1 receptor agonists used for weight management and asked manufacturers to remove that warning from affected labels. The agency said its evaluation did not identify an increased risk.

That's genuine reassurance.

It does not mean mood changes do not matter. Tell a prescriber about new or worsening symptoms, and do not stop or restart a prescription solely because of a headline.

For the full product-by-product picture, we're not going to rebuild it here. Our complete GLP-1 side effects guide covers current label warnings, common reactions, and symptoms that warrant prompt medical attention.

What happens if you stop a GLP-1 medication?

Randomized withdrawal studies show substantial average regain after treatment stops, while continued treatment preserves more of the loss. SURMOUNT-4 gives a clean result for people who had already tolerated high-dose tirzepatide, but it does not establish one best taper, maintenance dose, or stopping plan for everyone.

SURMOUNT-4 answered this the only way it can be answered honestly. Participants first received tirzepatide for 36 weeks and lost an average of 20.9%. Those who reached and tolerated 10 or 15 mg were then randomized to continue tirzepatide or switch to placebo.

From week 36 to week 88:

• The placebo group gained 14.0%.
• The continuing-tirzepatide group lost another 5.5%.
• 16.6% of the placebo group maintained at least 80% of the initial loss, versus 89.5% of the continuing group.

That's the finding. It's also population-specific. The randomized group had already made it through a 36-week lead-in and tolerated a high maintenance dose. It does not tell us exactly what happens to someone who stops earlier, stops at a lower dose, switches medications, or uses a structured maintenance program.

What people actually mean when they ask this question:

“I don't want to start something I can't stop or have to increase.”
— r/GLPGrad

“I'm scared of the side effects and unknown long term effects. Is it worth it?”
— r/glp1

“When the food noise went away, it was like freedom.”
— r/GLPGrad

These are short quotes from public forums. They show what readers are trying to figure out; they are personal experiences, not evidence. “Food noise” is a community term, not a standardized clinical endpoint.

What's still unknown

• Who can stop without major regain. We do not have a validated individual predictor.
• Whether tapering slowly changes long-term outcomes. This is not established for every drug.
• Whether a lower maintenance dose works after a particular treatment. Labels and evidence differ.
• How resistance training, nutrition, sleep, behavioral care, and other approved medication strategies alter maintenance.
• The optimal treatment duration for one individual.

Anyone claiming one universal answer is going beyond the evidence.

Questions worth asking before you stop

• Why am I stopping — cost, adverse effects, pregnancy planning, access, or because I reached a goal?
• What happened to appetite, weight, blood pressure, glucose, sleep apnea, or other conditions while I was on treatment?
• What is the monitoring plan if weight or symptoms return?
• Does my specific medication have a lower labeled maintenance option?
• What would make us restart, switch, or choose another treatment?
• What can I change now so the plan is not dependent on willpower alone?

For the broader mechanism and chronic-treatment context, see What is a GLP-1 medication?.

Why do GLP-1 medications work so much better for some people?

Response varies because of biology, drug choice, dose reached, time on treatment, tolerability, diabetes status, adherence, nutrition, activity, and affordability. A 2026 genetic study involving nearly 28,000 people found variants associated with response and gastrointestinal effects, but the effects were modest and no consumer genetic test can reliably choose your best GLP-1.

The 2026 genetics work is one of the most interesting new threads here. Researchers identified variants associated with differences in weight response and gastrointestinal adverse effects across almost 28,000 people.

It is a genuine step toward precision treatment.

It is not a product-ready decision tool. If someone offers you a genetic test that claims it can select your best GLP-1 with clinical certainty, they're selling ahead of the evidence.

The reasons that explain far more variation right now:

1. Which drug and mechanism you use.
2. Which dose you actually reach and tolerate.
3. How long you stay on treatment.
4. Whether you have type 2 diabetes; obesity trials commonly show smaller mean weight reductions in diabetes populations.
5. Baseline body weight, health conditions, and concurrent medication.
6. Adverse effects that cap dose or end treatment.
7. Nutrition, resistance exercise, sleep, and behavioral support.
8. Whether you keep taking it consistently.
9. Whether the medication remains affordable and available.

Persistence estimates vary widely by population, year, insurance status, product, and the gap used to define discontinuation. That is why a single internet statistic about “how many people quit” can be as misleading as a cross-trial weight-loss comparison.

The decision-relevant point is simpler: a medication cannot produce its trial result if you cannot obtain it, tolerate it, or keep using it long enough. Coverage and continuity are not side issues. They are part of effectiveness.

Where does compounded GLP-1 stand after the 2026 FDA actions?

Every efficacy result on this page comes from a specific FDA-approved product or an investigational product made for its clinical trial. Those findings do not establish the safety, effectiveness, quality, dose accuracy, or equivalence of a separately compounded preparation. In April 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list; that proposal is not a blanket ban on every patient-specific compounded prescription, and no final rule had been issued as of August 5, 2026.

Let's define the term, because it gets used loosely. Compounded means a licensed pharmacy or outsourcing facility prepares a medication under specific federal and state conditions rather than dispensing the finished FDA-approved product.

Compounding can be lawful and clinically legitimate in the right circumstances. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before they are marketed.

Where the rules stand

April 30, 2026 — FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulk-drug-substances list. That list concerns when registered outsourcing facilities may compound from bulk substances under section 503B.

July 30, 2026 — the extended public-comment period closed. The original draft said June 29; FDA extended it.

August 5, 2026 — no final decision had been issued.

This proposal is not the entire compounding law. Section 503A governs patient-specific pharmacy compounding under separate conditions. Neither 503A nor 503B provides a blanket right to make regular copies of commercially available approved drugs. The legal answer depends on the product, medical need, formulation, shortage status, prescriber, compounder, and statutory conditions.

The shortages that enabled broad copy-style compounding ended earlier: FDA determined the tirzepatide injection shortage resolved in 2024 and the semaglutide injection shortage resolved in February 2025.

FDA's unapproved-GLP-1 safety page reported that, as of May 31, 2026, it had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. Those are report counts, not rates. Reporting is incomplete; a report does not prove causation; and FDA says many state-licensed pharmacies are not required to submit every adverse-event report.

The July peptide meeting was not a GLP-1 authorization

On July 23 and 24, 2026, FDA's Pharmacy Compounding Advisory Committee considered seven non-GLP-1 substance groups: BPC-157, KPV, TB-500, MOTS-c, emideltide, epitalon, and Semax.

Those substances are not semaglutide, tirzepatide, liraglutide, retatrutide, CagriSema, or survodutide. Advisory committee discussion and votes are advice to FDA, not a final rule. Nothing at that meeting changed the legal status of GLP-1 products.

The retatrutide warning

This one is direct. There is no FDA-approved commercial retatrutide product. FDA has said retatrutide cannot be used in compounding under the federal exemptions because it is neither a component of an FDA-approved drug nor on an applicable bulks list.

A product sold as “retatrutide” outside a legitimate clinical trial has no FDA-verified identity, potency, purity, sterility, safety, or efficacy. That is different from saying laboratory analysis has proved every vial contains none of the molecule. The point is that no approved supply chain exists for consumer treatment.

If you want access to investigational retatrutide, the legitimate route is a registered clinical trial for which you qualify. Trial participation may involve randomization, placebo or comparator treatment, and no guarantee of receiving the experimental drug.

If cost is what's really driving your question, that's a different question from “which drug is strongest.” And it's a fair one. A legitimate plan has to fit the budget long enough to work.

→ Take the free 60-second GLP-1 path quiz to map approved, insurance, self-pay, and trial-search routes by your budget, medication preference, state, and coverage situation.

How do you read the next GLP-1 research headline yourself?

Before believing a GLP-1 headline, check eight things: humans or animals, randomized or observational, comparator, population, patient-important or surrogate endpoint, absolute and relative result, duration and estimand, and whether the complete result is peer-reviewed and approved for the use being discussed.

We'd rather teach you this than have you come back every time. Here's the checklist we use internally.

1. Humans or animals? Animal and cell results can justify a human trial. They do not establish a human treatment effect.

2. Randomized or observational? Random assignment is the strongest routine protection against treated and untreated groups being different before the treatment even begins. The Alzheimer’s story is the argument for asking.

3. Compared with what? Placebo, another drug, standard care, or nothing? “Better” is meaningless without the other half.

4. Who was in it? Age, sex, diabetes status, starting weight, existing disease, prior treatment, and geography. If the trial population does not resemble you, applicability drops.

5. What endpoint moved? Death, heart attack, hospitalization, pain, function, biopsy, lab value, imaging, or a survey? A surrogate can matter without being the same as a clinical outcome.

6. What were the absolute and relative numbers? “20% lower risk” and 6.5% versus 8.0% can be the same result. You need both.

7. How long, and which estimand? Week 26 and week 80 are different questions. Trial-product and treatment-policy numbers are different questions too.

8. Peer-reviewed and approved? A company release can contain important new data, but it is not a complete paper. A positive paper is not FDA approval. An approval for one indication is not approval for another.

Try it on a real headline

“New drug produces 30% weight loss.”

1. Humans? Yes.
2. Randomized? The parent trial was randomized.
3. Compared with what? The 80-week efficacy-estimand placebo group lost 2.2%.
4. Who? Adults with obesity or overweight; the 30.3% figure came from a prespecified extension of 532 participants who entered with BMI at least 35, completed week 80, tolerated treatment, and continued to week 104.
5. Endpoint? Percent body-weight change.
6. Absolute/relative? This is a mean body-weight percentage, not a risk reduction.
7. Duration and estimand? The 28.3% figure is the 80-week efficacy estimand; 25.0% is the treatment-regimen estimate; 30.3% is the week-104 extension result.
8. Peer-reviewed and approved? Company topline; complete paper pending; not FDA-approved.

Fair rewrite:

“In company-reported phase 3 results, investigational retatrutide produced 28.3% estimated mean weight loss at 80 weeks under an idealized efficacy estimand and 25.0% under the treatment-regimen estimand. A prespecified treatment-tolerant extension group averaged 30.3% at 104 weeks. The drug is not approved, has no announced FDA filing, and cannot be prescribed as an FDA-approved product.”

Same data. Completely different decision.

How did we build this GLP-1 research tracker, and what did we actually verify?

This tracker prioritizes FDA documents, current prescribing information, trial registries, and primary peer-reviewed publications. Every finding is coded for study design, population, estimand, publication status, regulatory status, practical meaning, and limitations, and every material change receives a dated entry below.

Our source order

1. FDA approval announcements, safety communications, approval letters, and current prescribing information.
2. ClinicalTrials.gov records.
3. Primary peer-reviewed randomized trials.
4. Systematic reviews and meta-analyses.
5. Large observational or genetic studies, clearly labeled.
6. Company releases only for material topline results, always labeled preliminary.
7. Reputable reporting for context when the primary record is not yet complete.
8. Forums and Reddit for reader language only, never medical, safety, or regulatory evidence.

What we verified

• FDA approval status, approval date, labeled indication, dose, and administration instructions.
• Study design, sample size, duration, population, comparator, and primary endpoint.
• Which statistical estimand produced each headline number.
• Placebo results and our active-minus-placebo arithmetic.
• Publication status: FDA-reviewed, peer-reviewed, sponsor topline, conference result, observational signal, or pending.
• Current commercial availability and manufacturer-stated cash pricing where included.
• Discontinuation rates where a primary source reported them.
• Current compounding proposal status and comment deadline.
• Whether a trial result has a matching current U.S. indication.

What we did not verify

• Whether any drug is right for you. We cannot do that and neither can another website.
• Individual outcomes described in forums or reviews.
• The identity or quality of products sold outside legitimate prescription, pharmacy, manufacturer, and clinical-trial channels.
• A commercial launch date for any investigational drug.
• A guaranteed FDA decision outcome or approval date.
• Every insurer's live formulary, prior-authorization rule, or negotiated copay.

Open items we will keep watching

• Retatrutide: full peer-reviewed TRIUMPH-1 and TRIUMPH-4 publications, remaining pivotal readouts, and any FDA filing.
• CagriSema: Novo Nordisk says it expects a U.S. decision in Q4 2026; FDA has not posted a public target date.
• Survodutide and oral pipeline drugs: later phase results and any regulatory submissions.
• FDA 503B bulks-list proposal: final agency action after the July 30 comment deadline.
• Pricing: manufacturer program changes, dose tiers, Medicare bridge eligibility, and expiration dates.

How often this updates

Monthly review on the first business day of each month. Immediate review after an FDA approval, label change, safety communication, major trial publication, trial termination, or correction.

When a company topline becomes a peer-reviewed paper, we do not silently replace it. We update the row, preserve the previous status in the change log, and explain whether the complete publication changed the interpretation.

We only change the “last verified” date when someone actually rechecks the sources. Not to look fresh.

Change log

Frequently asked questions about the latest GLP-1 research

What is the newest FDA-approved GLP-1 drug for weight loss?

Foundayo (orforglipron), approved April 1, 2026, is the newest new molecular entity in this group as of August 5, 2026. It is the first FDA-approved nonpeptide small-molecule GLP-1 tablet for chronic weight management. Wegovy HD, approved March 19, is a new higher dose of semaglutide; Wegovy tablets were approved December 22, 2025 and were the first oral GLP-1 product approved for chronic weight management.

Is retatrutide FDA-approved?

No. Retatrutide is investigational. Multiple phase 3 results have been announced, but no FDA application or approved commercial product has been announced. FDA has also stated that retatrutide cannot be used under the federal compounding exemptions.

When will retatrutide be available?

No company or agency has announced a commercial date. Trial completion, a regulatory filing, FDA review, approval, manufacturing, and launch would all have to occur. Any specific 2027 or 2028 pharmacy date is an estimate, not a verified schedule.

Is CagriSema approved?

No. Novo Nordisk submitted an NDA on December 18, 2025. The company says it expects a U.S. decision in Q4 2026, but the FDA has not posted a public target date and approval is not guaranteed.

Did semaglutide help Alzheimer's disease?

Not on the clinical outcome tested. EVOKE and EVOKE+ enrolled 3,808 people with early symptomatic, amyloid-confirmed Alzheimer's disease and found oral semaglutide did not slow clinical progression. The extension studies were stopped after the negative result.

Do GLP-1 drugs reduce alcohol cravings?

A small randomized phase 2 study of 48 non-treatment-seeking adults over nine weeks found improvement in some drinking and craving measures, but not all. Larger trials are needed. No GLP-1 drug is FDA-approved to treat alcohol use disorder.

Do GLP-1 drugs protect your heart?

Wegovy reduced major cardiovascular events in SELECT — 6.5% versus 8.0% — among adults who already had cardiovascular disease and overweight or obesity, without diabetes. That supports a specific FDA-labeled cardiovascular indication. It does not mean every GLP-1-based drug protects every heart.

Do GLP-1 drugs protect your kidneys?

FLOW found a 24% relative reduction in the primary kidney/cardiovascular composite with semaglutide in people with type 2 diabetes and chronic kidney disease. Other kidney populations need their own evidence.

Is tirzepatide approved for HFpEF?

No. SUMMIT produced strong randomized evidence in people with obesity-related HFpEF, but the current U.S. Zepbound label does not include an HFpEF indication.

Are GLP-1 pills as effective as injections?

The strongest approved injectable averages are larger in separate trials, but no direct randomized obesity trial has compared an approved pill with an approved injection under the same rules. For someone who will not use an injection, an appropriate pill they can take consistently may be the more effective practical choice.

Which approved GLP-1-based drug causes the most weight loss?

In SURMOUNT-5, tirzepatide produced greater mean weight loss than semaglutide — 20.2% versus 13.7% — in adults without type 2 diabetes at maximum tolerated doses over 72 weeks. That is the cleanest direct comparison between those two approved injectables. It is not a guarantee for one person or every dose.

Do GLP-1 drugs cause muscle loss?

Substantial weight loss can include fat and lean tissue. Lean mass is not identical to skeletal muscle, and function matters. A 2026 European consensus used a roughly 3:1 fat-to-lean loss ratio as a pragmatic reference, not a validated pass/fail target, and emphasized resistance exercise, adequate nutrition, waist measures, and functional monitoring.

Do GLP-1 drugs cause blindness?

An observational U.S. veteran study reported a higher relative risk of NAION after semaglutide initiation than after an SGLT2 inhibitor. The absolute event frequency was low, the design cannot prove causation, and the population was mostly older men. Sudden vision loss needs urgent same-day evaluation.

Is compounded semaglutide still legal?

Some patient-specific compounding can still be lawful when federal and state conditions are met. FDA's April 2026 proposal concerns whether semaglutide, tirzepatide, and liraglutide should appear on the 503B bulks list; it is not a blanket authorization or ban on every compounded prescription. Compounded products are not FDA-approved and receive no FDA premarket review for safety, effectiveness, or quality.

Does the July 2026 peptide meeting change anything for GLP-1 drugs?

No. The advisory committee considered seven non-GLP-1 substance groups: BPC-157, KPV, TB-500, MOTS-c, emideltide, epitalon, and Semax. Advisory committee recommendations are not final rules, and the meeting did not authorize compounded GLP-1 products.

Will I regain the weight if I stop?

Average regain was substantial in randomized withdrawal research. In SURMOUNT-4, participants who switched from tirzepatide to placebo gained 14.0% from week 36 to week 88, while those who continued lost another 5.5%. The randomized participants had already tolerated high-dose treatment, and no single taper or maintenance strategy has been established for everyone.

How often is this page updated?

Monthly, plus immediately after any material FDA action, label change, major safety communication, or pivotal trial publication. The last-verified date changes only when the listed sources are actually rechecked.

Where do I find GLP-1 clinical trials?

Use ClinicalTrials.gov. Search the drug or condition, filter to “Recruiting,” verify location and eligibility, and contact the study team listed in the registry. A trial may randomize participants to placebo or another treatment and does not guarantee access to the experimental drug.

The bottom line

The latest GLP-1 research says something simpler than the headlines suggest.

Two newer options became available in 2026. Wegovy HD added a 7.2 mg semaglutide dose for certain adults who already tolerate 2.4 mg. Foundayo added the first FDA-approved nonpeptide small-molecule GLP-1 tablet for chronic weight management, with regular cash pricing that rises by dose from $149 to $349.

The drug behind the biggest number is not approved, and no verified launch date exists. The 28.3% and 25.0% retatrutide figures answer different estimand questions. The 30.3% result came from a prespecified treatment-tolerant extension group at 104 weeks.

The strongest evidence beyond weight loss is real and specific — cardiovascular outcomes, kidney outcomes, selected liver disease, obesity-related HFpEF, and sleep apnea — but trial success and FDA indication are not interchangeable. Tirzepatide's HFpEF result is strong; HFpEF is not a current Zepbound indication.

And the honest failures matter. The Alzheimer's story did not hold up in two large randomized phase 3 trials. CagriSema did not match tirzepatide in its later noninferiority test. That's not a reason to distrust the field. It's a reason to trust complete trials over the easiest headline.

Do not let an investigational press-release number be the sole reason you delay a clinician-recommended approved option. And do not let an approval announcement pressure you into a drug that is not medically, financially, or practically sustainable for you.

Whichever you decide, decide it on the real numbers.

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

Get a personalized action map based on your insurance, medication preference, state, and budget. The quiz does not determine medical eligibility or recommend a prescription — it shows you which legitimate paths may exist for your situation and what to verify next.

Sources

FDA and current prescribing information

• FDA approval announcement: Foundayo/orforglipron — April 1, 2026
• Foundayo U.S. prescribing information
• Foundayo official savings and cash-price terms
• FDA announcement: higher-dose semaglutide/Wegovy HD — March 19, 2026
• Wegovy U.S. prescribing information: tablets, pen, Wegovy HD, cardiovascular and MASH indications
• NovoCare current Wegovy pricing
• Zepbound U.S. prescribing information
• FDA safety communication: suicidal behavior and ideation warning removal
• FDA concerns with unapproved GLP-1 drugs used for weight loss
• FDA proposed 503B bulks-list rule
• FDA Pharmacy Compounding Advisory Committee meeting information — July 23–24, 2026

Pivotal trials and sponsor results

• TRIUMPH-1 retatrutide topline — Eli Lilly, May 21, 2026
• TRIUMPH-4 retatrutide topline — Eli Lilly, December 11, 2025
• CagriSema FDA submission — Novo Nordisk, December 18, 2025
• Novo Nordisk Q1 2026 investor presentation — CagriSema Q4 expectation
• REDEFINE 1: CagriSema in adults with overweight or obesity
• SYNCHRONIZE-1: survodutide phase 3
• SURMOUNT-5: tirzepatide versus semaglutide
• SELECT: semaglutide and cardiovascular outcomes
• FLOW: semaglutide and kidney outcomes
• SUMMIT: tirzepatide in obesity-related HFpEF
• SURMOUNT-4: tirzepatide withdrawal
• EVOKE and EVOKE+: oral semaglutide in early Alzheimer's disease
• Semaglutide in alcohol use disorder — JAMA Psychiatry
• Semaglutide and NAION target-trial emulation
• Elecoglipron VISTA phase 2 trial
• Pfizer berobenatide phase 2b and VESPER-6 update
• Acmopatide type 1 diabetes phase 2 registry
• GLP-1 response genetics — Nature
• European consensus on incretin therapy and body composition

Access and pricing verification

• Ro GLP-1 Insurance Coverage Checker
• Ro Body membership and medication pricing
• Weight Loss Provider Guide GLP-1 cost guide

Reddit quotes are from public posts in r/glp1 and r/GLPGrad and are used only to illustrate what readers are asking. They are not medical evidence.